GLP-1 Medications & Weight Loss Treatment in South America

Overview

GLP-1 receptor agonists have transformed the treatment of obesity and type 2 diabetes worldwide. These injectable medications, originally developed for blood sugar control, have shown remarkable effectiveness for sustainable weight loss, with clinical trials demonstrating average reductions of 15-20% of total body weight. As demand for these treatments grows across South America, understanding how they work, who qualifies, and how to access them safely in Argentina and Brazil is essential.

Obesity rates in South America have risen significantly over the past two decades. In Argentina, roughly 28% of adults are classified as obese, while Brazil reports similar numbers with over 26% of its adult population affected. These figures have driven strong interest in medical weight management options beyond traditional diet and exercise alone. However, GLP-1 medications are prescription treatments that require careful medical supervision. Self-medicating or obtaining these drugs without proper evaluation can lead to serious health consequences, including pancreatitis, gallbladder disease, and dangerous interactions with other medications.

At CareThere, we believe that effective weight management starts with a thorough medical assessment. Our physicians evaluate your complete health profile before recommending any treatment, ensuring that GLP-1 therapy is both safe and appropriate for your individual situation.

How GLP-1 Medications Work

GLP-1 stands for glucagon-like peptide-1, a naturally occurring hormone produced in the gut after eating. This hormone plays several critical roles in metabolism: it stimulates insulin release from the pancreas, suppresses glucagon secretion (which reduces liver glucose production), and slows gastric emptying so food moves through the stomach more gradually.

GLP-1 receptor agonist medications mimic and amplify the effects of this natural hormone. When injected subcutaneously (typically once weekly for semaglutide), they activate GLP-1 receptors throughout the body, including in the brain. In the hypothalamus, these medications reduce appetite signals and increase feelings of fullness, leading patients to naturally consume fewer calories without the intense hunger that undermines most diets.

Beyond appetite suppression, GLP-1 medications offer several metabolic benefits. They improve insulin sensitivity, reduce visceral fat (the dangerous fat surrounding internal organs), lower systemic inflammation, and have demonstrated cardiovascular protective effects. The SELECT trial showed that semaglutide reduced major cardiovascular events by 20% in overweight or obese patients, regardless of whether they had diabetes. These broad metabolic improvements make GLP-1 therapy particularly valuable for patients with metabolic syndrome.

Available Medications

Several GLP-1 receptor agonists are currently available in South America, though availability and brand names vary by country.

Semaglutide is the most widely prescribed GLP-1 medication. In Argentina, Ozempic (semaglutide 0.25mg, 0.5mg, and 1mg) is approved by ANMAT for type 2 diabetes and is available in major pharmacies. Wegovy (semaglutide 2.4mg), the higher-dose formulation specifically approved for weight management, has more limited availability but can be obtained through specialty pharmacies. In Brazil, both Ozempic and Wegovy are approved by ANVISA, with Ozempic widely stocked in major pharmacy chains such as Drogasil and Pacheco. Wegovy became available in Brazilian pharmacies in late 2024 and supply has stabilized considerably.

Liraglutide (marketed as Saxenda for weight loss and Victoza for diabetes) is a daily injectable GLP-1 agonist available in both Argentina and Brazil. While effective, its daily injection requirement makes it less convenient than weekly semaglutide.

Tirzepatide (Mounjaro), a dual GIP/GLP-1 receptor agonist, has shown even greater weight loss in clinical trials (up to 22.5% body weight reduction). It received ANVISA approval in Brazil and is gradually entering the Argentine market through ANMAT authorization. Availability remains more limited compared to semaglutide.

Who Is a Candidate

GLP-1 medications for weight management are generally indicated for adults meeting specific clinical criteria. Standard guidelines recommend these medications for patients with a BMI of 30 or greater (obesity), or a BMI of 27 or greater (overweight) with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea.

Metabolic syndrome is a particularly strong indication for GLP-1 therapy. This condition is diagnosed when a patient presents with three or more of the following: waist circumference greater than 102 cm in men or 88 cm in women, fasting triglycerides above 150 mg/dL, HDL cholesterol below 40 mg/dL in men or 50 mg/dL in women, blood pressure above 130/85 mmHg, or fasting blood glucose above 100 mg/dL. Patients with metabolic syndrome benefit from the broad metabolic improvements that GLP-1 medications provide beyond weight loss alone.

Contraindications include personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2), a history of pancreatitis, severe gastrointestinal disease, and pregnancy or breastfeeding. Patients with a history of eating disorders should be evaluated carefully, as appetite-suppressing medications may complicate recovery.

Starting Treatment

Initiating GLP-1 therapy requires a comprehensive medical evaluation. At CareThere, this assessment includes a complete medical history review, physical examination, and baseline laboratory work including fasting glucose, HbA1c, lipid panel, liver function tests, kidney function (creatinine and eGFR), thyroid function (TSH), and a complete blood count.

Semaglutide follows a gradual dose titration schedule to minimize gastrointestinal side effects. Treatment typically begins at 0.25mg weekly for four weeks, then increases to 0.5mg for another four weeks. Depending on response and tolerability, the dose continues to escalate at four-week intervals through 1mg, 1.7mg, and ultimately 2.4mg weekly for the weight management indication. This slow escalation over 16-20 weeks allows the body to adjust and significantly reduces nausea and other GI symptoms.

Ongoing monitoring is essential. We recommend follow-up consultations at four weeks, eight weeks, and then every three months. Repeat blood work at three and six months helps track metabolic improvements and identify any adverse effects early. Weight, blood pressure, and waist circumference are measured at each visit to assess treatment response.

Common Side Effects & Management

The most frequently reported side effects of GLP-1 medications are gastrointestinal. Nausea affects approximately 40-45% of patients during dose escalation but typically improves within the first few weeks at each dose level. Eating smaller, more frequent meals, avoiding high-fat or greasy foods, and staying well-hydrated can significantly reduce nausea. Some patients also experience vomiting (around 25%), diarrhea (30%), and constipation (24%), which are usually mild to moderate and transient.

Injection site reactions such as redness, swelling, or itching occur in approximately 5-10% of patients and can be managed by rotating injection sites between the abdomen, thigh, and upper arm.

Serious but uncommon risks include acute pancreatitis (presenting as severe, persistent abdominal pain radiating to the back), gallbladder disease (especially in patients losing weight rapidly), and an increased risk of thyroid C-cell tumors observed in rodent studies. While the thyroid risk has not been confirmed in humans, GLP-1 medications carry a boxed warning and are contraindicated in patients with relevant thyroid cancer history. Patients should be counseled to report any persistent neck mass, difficulty swallowing, or hoarseness promptly.

Lifestyle & Complementary Approaches

GLP-1 medications work best as part of a comprehensive weight management plan that includes dietary modification, physical activity, and behavioral changes. The medications reduce appetite and make it easier to adhere to a caloric deficit, but sustainable results depend on building healthy habits that continue beyond medication use.

Dietary modifications should focus on increased protein intake (1.2-1.6g per kilogram of body weight daily) to preserve lean muscle mass during weight loss. Patients should prioritize vegetables, whole grains, and lean proteins while reducing ultra-processed foods, sugary beverages, and excessive alcohol consumption. Because GLP-1 medications slow gastric emptying, patients often find they cannot eat the same volumes as before and should focus on nutrient-dense foods to ensure adequate nutrition.

Physical activity recommendations include at least 150 minutes of moderate-intensity aerobic exercise weekly (brisk walking, cycling, or swimming) combined with resistance training two to three times per week. Resistance training is particularly important to preserve muscle mass and maintain metabolic rate during active weight loss.

Behavioral support, including regular check-ins with a healthcare provider and attention to sleep quality, stress management, and emotional eating patterns, rounds out a comprehensive approach that maximizes long-term outcomes.

Getting GLP-1 Treatment with CareThere

CareThere offers a streamlined path to medically supervised GLP-1 treatment for patients in Argentina, Brazil, and those visiting South America. Our process begins with a telemedicine consultation starting at $40 USD, during which a licensed physician reviews your health history, current medications, and weight management goals to determine if GLP-1 therapy is appropriate.

If you qualify, your physician will issue a prescription valid at local pharmacies in Argentina or Brazil. We guide you through obtaining the medication, including identifying pharmacies with current stock and navigating local prescription requirements. For patients who prefer in-person care, CareThere also coordinates home visits and clinic appointments in Buenos Aires and major Brazilian cities.

Ongoing monitoring is a core part of our service. Your CareThere physician schedules regular follow-up appointments to track progress, adjust dosing, review blood work, and address any side effects. We maintain secure digital health records so your care remains coordinated and consistent, whether you are at home or traveling.

Frequently Asked Questions

How much do GLP-1 medications cost in Argentina and Brazil? Ozempic costs approximately $190-200 USD per month in Argentina and $170-190 USD (R$963-1,063) in Brazil at major pharmacies. Wegovy ranges from $160-350 USD (R$900-2,000) in Brazil depending on dosage, with limited availability in Argentina. Mounjaro runs $480-650 USD per month in Argentina and $170-670 USD (R$970-3,836) in Brazil depending on dose. All prices are significantly lower than in the United States, where the same medications exceed $900-1,100 monthly without insurance. CareThere can help you find current pricing at local pharmacies.

Do I need a prescription to buy Ozempic in South America? Yes. Both Argentina and Brazil require a valid medical prescription for GLP-1 medications. CareThere physicians can provide the appropriate prescriptions following a proper medical evaluation.

Can I start GLP-1 treatment via telemedicine? In some cases, an initial telemedicine consultation may be sufficient to evaluate candidacy. However, GLP-1 therapy requires a thorough medical evaluation including baseline blood work, and some patients may need an in-person assessment depending on their health profile. Your CareThere physician will determine the best approach for your situation.